Treating Oral Yeast Infection

Study: Once-Daily Tablet as Effective as Multiple Pill Dosings for Treating Oral Yeast Infection in HIV/AIDS Patients

DETROIT - A once-daily medication option for treating the most common mouth infection in HIV/AIDS patients has shown to be just as effective and safe as taking an anti-fungal pill five times a day, according to a Henry Ford Hospital study.

Researchers found that a small tablet applied daily that sticks to the gum and dissolves inside the mouth with few or no side effects is a novel, convenient option for treating an infection called oral candidiasis (OC), which occurs in about one third to one half of HIV patients and up to 90 percent of AIDS patients.

The study is believed to be the largest to date involving HIV/AIDS patients with OC. The infection is also common in patients suffering from many forms of cancer, especially those with head and neck cancer, in which the infection rate is as high 77 percent.

The study is being presented at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco.

"This is an exciting new, convenient way for treating this infection," says Jose A. Vazquez, M.D., the study's lead author and a Henry Ford Infectious Disease physician.

"It's a tablet that you just stick on the gum and it releases an anti-fungal agent over the course of six to eight hours. Because the anti-fungal agent stays in the mouth, it provides the same relief as the oral medication but with few or no side effects."

Dr. Vazquez says medication taken orally or by injection often is absorbed into other parts of the body, thus causing side effects for patients such as nausea, vomiting, diarrhea and liver dysfunction.

The study compared the effectiveness and safety of taking 50 milligrams of a miconazole mucoadhesive buccal tablet once-daily to 10 milligrams of clotrimazole, a common anti-fungal pill five times a day. Of the 578 patients enrolled in the randomized study, 291 received the tablet and 287 received the clotrimazole pill.

SOURCE:http://henryford.com

For information regarding Prostate Cancer, Robotic Prostatectomy, Other Robotic Procedures, Vattikuti Urology Institute visit www.drmanimenon.com

The Vattikuti Urology Institute

K9, 2799 W. Grand Blvd.

Detroit MI 48202

2010 IRUS

On behalf of the Vattikuti Urology Institute and Henry Ford Hospital, it is my great pleasure to invite you to participate in our 2010 International Robotic Urology Symposium. Our theme of "Advance" continues, looking to the future with improved technique development.

Our stimulating scientific program will feature numerous live 3-D operative demonstrations, as well as critique panels covering the foremost topics in robotic urology.

We are very excited to showcase the critique panels format in January. The world's leaders in robotic surgery will debate the advantages and disadvantages of techniques and share competing views on numerous topics, which will also invite registrant participation.

Our program will be held at the magnificent Wynn Las Vegas and will include an opportunity to see the acclaimed show Le Rêve.

I look forward to seeing you at the Wynn Las Vegas!


Mani Menon, M.D., FACS
The Raj and Padma Vattikuti Distinguished Chair
Director, Vattikuti Urology Institute
Henry Ford Health System

Nerve-Sparing Technique Proves To Be Better

The Veil of Aphrodite results in significantly better erectile function outcomes.

Surgeons at the Vattikuti Urology Institute pioneered a new technique of nerve-sparing robotic prostatectomy. The "Veil of Aphrodite" results in significantly better erectile function outcomes than for patients who receive conventional nerve-sparing surgery, and without compromising cancer control.

Best-Published Erectile Function Outcomes
Sexual function was assessed a year following surgery by a questionnaire of men with no pre-existing erectile dysfunction who underwent robotic radical prostatectomy incorporating the Veil of Aphrodite. Depending on your pre-existing erectile dysfunction, you may or may not achieve similar results.

	Veil of Aphrodite nerve-sparing	Conventional nerve-sparing
Men had erections strong enough for intercourse	97 percent	74 percent
Men had erections that were normal	85 percent	26 percent
Men had normal erections without medications	51 percent	17 percent

The radar graph shows pre-operative and post-operative scores in each patient and the ability of the procedure to preserve sexual function. The blue areas represent the measured loss of erectile function after surgery. The smaller the blue area, the better the outcome. Patients who had the Veil of Aphrodite did better than patients who had a conventional nerve-sparing procedure.

The technique of the operation and the results of the year-long study were published in numerous medical journals. The potency outcomes are the highest reported to date. These results should help ease men's concern as to the future of their sex lives when faced with a radical prostatectomy, the surgical removal of the prostate and surrounding tissue.

Success Of Vattikuti Urology Institute

Nearly 5,000 Robotic Surgeries and counting.

More than any other hospital in the world.

Robotic prostate surgery started here - pioneered by Mani Menon, M.D., and the Vattikuti Urology Institute.

No surgical team in the world has more experience performing robotic prostatectomy, a procedure that not only removes the cancer but also has a high probability of preserving sexual function and urinary control. We also were one of the first facilities in the world to use robotic surgery for removing kidney cancer and bladder cancer with reconstruction.

Patients from all 50 states and more than two dozen countries have traveled to the Vattikuti Urology Institute. Learn more about Robotic Surgery.

Leaders in Urology
The Vattikuti Urology Institute is a comprehensive clinical, research and teaching institute that consistently ranks among the best in the nation. Here you will find some of the world's first and most progressive approaches to treating prostate cancer and other urological conditions.

The Vattikuti Urology Institute:

• Was named a "Best Hospital" for Urology by U.S. News and World Report for 2009.

• Uses the daVinci Surgical system.
  

• Has dedicated more than $20 million to basic and clinical urology research.

• Hosts the International Robotic Urology Symposium, which attracts physicians from around the world interested in learning robotic surgery from Dr. Menon and his team.

• Is committed to training the next generation of highly skilled robotic surgeons. Our physicians and fellows helped establish urologic robotic surgery programs at New York-Presbyterian/Weill Cornell, New York-Presbyterian Hospital/Columbia University Medical Center, and Hospital of the University of Pennsylvania, among others.

• Maintains a database - considered to be the most comprehensive of its kind in the world - of more than 6,000 patients with prostate cancer to determine the most effective therapies.

• Is the only center in the world offering suicide gene therapy - developed in the Henry Ford Department of Radiation Oncology and currently in Phase III clinical trial - as a way to eliminate prostate cancer cells without damaging surrounding normal tissue.

With top clinicians and researchers, the Vattikuti Urology Institute offers a comprehensive, multidisciplinary approach, backed by evidence-based medicine, to ensure the best outcome for each patient.

Visit: http://www.henryford.com

http://www.drmanimenon.com

Robotic Radical Cystectomy

Robotic surgery to remove the bladder for large tumors or disease. Radical cystectomy remains the standard treatment for muscle invasive bladder cancer. However laparoscopic radical cystectomy remains extremely technically challenging even for experienced laparoscopic surgeons. Following the successful application of the da Vinci robotic surgical system for radical prostatectomy, attention has now turned to the use of robot assistance for laparoscopic cystectomy. The surgery includes removal of the bladder and the removal of the prostate in men and the uterus, ovaries, cervix, and part of the vagina in women. After the removal of the bladder, a piece of the intestine is reconstructed to enable the diversion, storage, and passage of urine. The Vattiktui Urology Institute has played a important role in the development of the robotic cystectomy and patients with bladder cancer receive care from pioneering and experienced surgeons.
Source: www.drmanimenon.com